|Last Price$0.06||Day Change (%)10.00%|
|Open Price$0.05||Day Change ($)0.00|
|Day Range0.04–0.06||52-Week Range0.03–1.00|
As of Thu 3/26/2015 2:48:00 PM | USD
IMS Health Announces Pricing of Senior Notes to Finance Proposed Acquisition of Cegedim’s CRM and Strategic Data Businesses
Mylan Launches First and Only Available Intermediate Dosage Strengths of Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr
Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015
Mylan Launches Generic Subutex® Sublingual Tablets
FDA approves first biosimilar drug
FDA Warns on Low-Testosterone Drugs -- Update
Despite the Fed taper, a U.S. economy struggling to shake off the winter blues, and a slowing China, stocks continued their remarkable winning streak from April through June.
IMS Health is on the right track for growth.
A look back at the winners and losers of the final quarter of a tumultuous year.